Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant natural dendritic cell vaccination versus placebo in resected stage IIIB/IIIC melanoma
NL-OMON45943Phase 3Active, not recruiting
- Sponsor
- Tumor Immunology
- Start
- Dec 2016
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma (2 arms), sponsored by Tumor Immunology. Primary endpoint: 2-year recurrence-free survival rate. Started Dec 2016; status: active, not recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON45943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45943.